Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | PTEN | P60484 | 1/20 | 0.41 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL25267642 | 0.92 | FFAR1 (0.44) | KEAP1FFAR1FFAR4CES2CES1 | |
| SCHEMBL24264807 | 0.88 | SMN1; SMN2 (0.53) | FFAR1FFAR4CES2CES1 | |
| SCHEMBL30427994 | 0.86 | MAPT (0.53) | — | |
| SCHEMBL28122739 | 0.85 | KEAP1 (0.48) | KEAP1FFAR1FFAR4NPSR1PTPRB | |
| SCHEMBL25219212 | 0.83 | KEAP1 (0.47) | KEAP1FFAR1FFAR4THRATHRB | |
| SCHEMBL585200 | 0.83 | NPSR1 (0.48) | KEAP1FFAR1FFAR4NPSR1THRA | |
| SCHEMBL14430390 | 0.82 | FFAR1 (0.50) | FFAR1FFAR4 | |
| SCHEMBL30873958 | 0.81 | FFAR1 (0.62) | KEAP1FFAR1FFAR4CA1CA2 | |
| SCHEMBL5670212 | 0.81 | KEAP1 (0.64) | KEAP1FFAR1FFAR4NPSR1PTPRB | |
| SCHEMBL30572365 | 0.81 | CAPN1 (0.44) | FFAR1FFAR4CES2CES1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-116209433-B | Small molecule albumin binding agents | 俄勒冈健康科学大学 | 2025-05-23 | — | — | CN | disclosed |
| CN-119528923-A | Tri-fused ring compound and preparation method and application thereof | 韦恩生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119013287-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118613490-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-09-06 | — | — | CN | disclosed |
| WO-2024158775-A1 | PYRIDAZINES AS SARM1 INHIBITORS | DISARM THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-118076623-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| CN-117940445-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2022040607-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040607-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-02-24 | — | — | WO | disclosed |
| US-9518222-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-13 | — | — | US | disclosed |
| US-20160046864-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2016-02-18 | — | — | US | disclosed |
| US-8188082-B2 | 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2125823-B1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | KEAP1 534/4885FFAR1 4246/4885FFAR4 4580/4885 |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | KEAP1 1215/4885FFAR1 192/4885FFAR4 191/4885 |
| US-20160046864-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD1, YBX1, LEF1 | KEAP1 1506/4885FFAR1 1197/4885FFAR4 1685/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | KEAP1 534/4885FFAR1 4246/4885FFAR4 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.